UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care

European journal of gastroenterology & hepatology, 2017-06, Vol.29 (6), p.646-650

2017

Volltextzugriff (PDF)

Thromboembolism as an important complication of inflammatory bowel disease

European journal of gastroenterology & hepatology, 2016-01, Vol.28 (1), p.1-7

2016

Volltextzugriff (PDF)

Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis

Clinical gastroenterology and hepatology, 2006-06, Vol.4 (6), p.760-765

2006

Volltextzugriff (PDF)

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Inflammatory bowel diseases, 2018-04, Vol.24 (5), p.1099-1105

2018

Volltextzugriff (PDF)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials

BMC gastroenterology, 2024-03, Vol.24 (1), p.121-12, Article 121

2024

Volltextzugriff (PDF)

Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis

Inflammatory bowel diseases, 2014-07, Vol.20 (7), p.1198-1207

2014

Volltextzugriff (PDF)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD

BMJ open gastroenterology, 2023-02, Vol.10 (1), p.e001003

2023

Volltextzugriff (PDF)

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2015-06, Vol.148 (7), p.1320-1329.e3

2015

Volltextzugriff (PDF)

Efficacy of JAK inhibitors in Ulcerative Colitis

Journal of Crohn's and colitis, 2020-08, Vol.14 (Supplement_2), p.S737-S745

2020

Volltextzugriff (PDF)

The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long‐term clinical outcomes in patients with ulcerative colitis

Alimentary pharmacology & therapeutics, 2024-01, Vol.59 (1), p.64-70

2024

Volltextzugriff (PDF)

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

Clinical gastroenterology and hepatology, 2016-04, Vol.14 (4), p.543-549

2016

Volltextzugriff (PDF)

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2020-02, Vol.158 (3), p.537-549.e10

2020

Volltextzugriff (PDF)

Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

Gut, 2018-01, Vol.67 (1), p.43-52

2018

Volltextzugriff (PDF)

Targeting TNF-α for the treatment of inflammatory bowel disease

Expert opinion on biological therapy, 2014-01, Vol.14 (1), p.75-101

2014

Volltextzugriff (PDF)

Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patients

Journal of gastroenterology and hepatology, 2019-07, Vol.34 (7), p.1175-1181

2019

Volltextzugriff (PDF)

Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2024-03, Vol.166 (3), p.483-495

2024

Volltextzugriff (PDF)

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2018-11, Vol.12 (11), p.1316-1325

2018

Volltextzugriff (PDF)

Optimising infliximab induction dosing for patients with ulcerative colitis

British journal of clinical pharmacology, 2019-04, Vol.85 (4), p.782-795

2019

Volltextzugriff (PDF)

Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative Colitis

Journal of Crohn's and colitis, 2019-09, Vol.13 (10), p.1351-1361

2019

Volltextzugriff (PDF)

Immunogenicity to infliximab is associated with HLA-DRB1

Gut, 2015-08, Vol.64 (8), p.1344-1345

2015

Volltextzugriff (PDF)

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis

Clinical gastroenterology and hepatology, 2015-03, Vol.13 (3), p.531-538

2015

Volltextzugriff (PDF)

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

Therapeutic drug monitoring, 2019-06, Vol.41 (3), p.317-324

2019

Volltextzugriff (PDF)

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis

Journal of Crohn's and colitis, 2017-01, Vol.11 (1), p.53-59

2017

Volltextzugriff (PDF)

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

Clinical gastroenterology and hepatology, 2022-01, Vol.20 (1), p.105-115.e14

2022

Volltextzugriff (PDF)

A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis

Inflammatory bowel diseases, 2020-03, Vol.26 (4), p.570-580

2020

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

ThemaColitis, Ulcerative - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(49)
Life Sciences & Biomedicine
(48)
Science & Technology
(48)
Gastroenterology & Hepatology
(42)
Female
(39)
Male
(37)
Adult
(35)
Treatment Outcome
(27)
Middle Aged
(25)
Ulcerative Colitis
(25)
Crohn Disease - Drug Therapy
(19)
Inflammatory Bowel Disease
(16)
Retrospective Studies
(16)
Infliximab
(14)
Remission Induction
(11)
Severity Of Illness Index
(11)
Antibodies, Monoclonal - Therapeutic Use
(10)
Colitis, Ulcerative - Diagnosis
(10)
Gastrointestinal Agents - Therapeutic Use
(10)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care

Thromboembolism as an important complication of inflammatory bowel disease

Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials

Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Efficacy of JAK inhibitors in Ulcerative Colitis

The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long‐term clinical outcomes in patients with ulcerative colitis

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

Targeting TNF-α for the treatment of inflammatory bowel disease

Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patients

Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

Optimising infliximab induction dosing for patients with ulcerative colitis

Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative Colitis

Immunogenicity to infliximab is associated with HLA-DRB1

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis

Aktive Filter

Suchergebnisse filtern